Skip to main content
Premium Trial:

Request an Annual Quote

Gentronix, Apredica to Collaborate on Predictive Toxicology

NEW YORK (GenomeWeb News) – Gentronix and Apredica said today that they will collaborate on providing drug-discovery support services with a focus on predictive toxicology.

Watertown, Mass.-based Apredica is an ADME-Tox contract research laboratory and has been working with Gentronix on developing "a joint predictive toxicology offering based on a set of assays that accurately predict many known mechanisms of human toxicities," the firm's president, Katya Tsaioun, said in a statement.

Manchester, UK-based Gentronix develops assays for genotoxicity based on its GeneScreen and BlueScreen human cell assay technologies.

Financial and further terms of the alliance were not disclosed.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.